Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Pharmacology and Therapeutics|September 27, 2024
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular LymphomaChi-Chung Li, Brendan Bender, Justin Wilkins, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 20, 2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumorsMark W Kieran, Susan Chi, Stewart Goldman, et al.
Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 3, 2017
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseHongshan Li, Jingyu Yu, Chao Liu, et al.
Clinical and Translational Science|April 25, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular LymphomaJunyi Li, Michael Z Liao, Justin Wilkins, et al.
Journal for Immunotherapy of Cancer|August 10, 2019
Immunogenicity of pembrolizumab in patients with advanced tumorsMarianne J H van Vugt, Julie A Stone, Rik H J M M De Greef, et al.
Cancer Research|November 16, 2014
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsAnna E Vilgelm, Jeff S Pawlikowski, Yan Liu, et al.
Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
Pageof 3